PT1512014E - Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante - Google Patents

Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante Download PDF

Info

Publication number
PT1512014E
PT1512014E PT03738030T PT03738030T PT1512014E PT 1512014 E PT1512014 E PT 1512014E PT 03738030 T PT03738030 T PT 03738030T PT 03738030 T PT03738030 T PT 03738030T PT 1512014 E PT1512014 E PT 1512014E
Authority
PT
Portugal
Prior art keywords
antigens
allo
cancer
identification
alo
Prior art date
Application number
PT03738030T
Other languages
English (en)
Inventor
Wolfgang Strittmatter
Heidrun Moll
Burkhard Scharm
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PT1512014E publication Critical patent/PT1512014E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
PT03738030T 2002-06-13 2003-06-13 Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante PT1512014E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02013423 2002-06-13

Publications (1)

Publication Number Publication Date
PT1512014E true PT1512014E (pt) 2009-11-10

Family

ID=29724392

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03738030T PT1512014E (pt) 2002-06-13 2003-06-13 Método de identificação de alo-antigénios e sua utilização para terapia de cancro e transplante

Country Status (11)

Country Link
US (1) US20050244421A1 (pt)
EP (2) EP1512014B1 (pt)
JP (2) JP2005529187A (pt)
AT (2) ATE438857T1 (pt)
AU (1) AU2003245942B2 (pt)
CA (1) CA2489296A1 (pt)
DE (1) DE60328685D1 (pt)
DK (1) DK1512014T3 (pt)
ES (2) ES2329461T3 (pt)
PT (1) PT1512014E (pt)
WO (1) WO2003106692A2 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106692A2 (en) * 2002-06-13 2003-12-24 Merck Patent Gmbh Methods for the identification of all-antigens and their use for cancer therapy and transplantation
JP2005102599A (ja) * 2003-09-30 2005-04-21 Shimadzu Corp Ｈｌａタイピング法
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
PL1866328T3 (pl) * 2005-03-22 2011-05-31 Rohto Pharma Peptydy zwiększające wytwarzanie kolagenu lub kwasu hialuronowego
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US20090186042A1 (en) * 2006-02-27 2009-07-23 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
KR101738323B1 (ko) 2007-09-19 2017-05-19 플루리스템 리미티드 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도
US20120165211A1 (en) * 2007-09-20 2012-06-28 Bracco Imaging S.P.A. Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques
AU2008300516A1 (en) * 2007-09-20 2009-03-26 Bracco Imaging Spa Method for the preparation of new oligoclonal antibodies
JP2011520425A (ja) * 2008-04-18 2011-07-21 ザ ユニバーシティー オブ テネシー リサーチ ファウンデーション 一塩基多型（ｓｎｐ）および免疫寛容の誘導に対する耐性との関連
EP2303293A1 (en) * 2008-05-27 2011-04-06 Pluristem Ltd. Methods of treating inflammatory colon diseases
JPWO2010026735A1 (ja) * 2008-09-05 2012-01-26 国立大学法人名古屋大学 アミロイドβ凝集促進ペプチド及びその用途
KR102095670B1 (ko) 2010-05-14 2020-03-31 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
EP2612149B1 (en) * 2010-06-21 2017-08-09 Innatoss Laboratories B.V. Compositions and methods for diagnosing and monitoring disease and treatment via antigen-specific molecules
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
RU2508552C2 (ru) * 2011-06-17 2014-02-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Минздравсоцразвития России" Способ прогнозирования развития злокачественных солидных опухолей у детей и подростков
EP2823040B1 (en) * 2012-03-06 2018-08-01 Cellect Biotherapeutics Ltd. Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2932787A1 (en) * 2013-12-06 2015-06-11 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
AU2015315005B9 (en) 2014-09-10 2021-08-12 Genentech, Inc. Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
KR102833333B1 (ko) 2016-01-08 2025-07-11 니코데 테라퓨틱스 에이에스에이 치료적 항암 네오에피토프 백신
MX2019003176A (es) * 2016-09-23 2019-07-04 Hutchinson Fred Cancer Res Receptores de linfocitos t (tcr) especificos del antigeno menor de histocompatibilidad (h) ah-1 y sus usos.
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN110996970A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化癌症疫苗的方法
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
US12406510B2 (en) * 2021-03-26 2025-09-02 Howard University Method for the detection, segmentation and morphological mapping on neural cell images of the whole brain

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837477A (en) * 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5770201A (en) 1994-12-23 1998-06-23 Rijsuniversiteit Te Leiden HA-2 antigenic peptide
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
PT840750E (pt) * 1995-07-25 2006-07-31 Univ Leiden Peptido antigenico de ha-2
DE69637524D1 (de) 1995-07-27 2008-06-26 Univ Leiden Das h-y antigen
DE69833120T2 (de) 1997-07-23 2007-03-01 Rijksuniversiteit Leiden Verfahren zur Typisierung des HA-1 Nebenhistokompatibilitätsantigens
EP1020519A1 (en) * 1999-01-15 2000-07-19 Introgene B.V. Minor histocompatibility antigens and their use in the diagnosis and treatment of tumors
EP1067141A1 (en) 1999-06-11 2001-01-10 Rijksuniversiteit te Leiden A male-specific protein homologue involved in histocompatibility
AU2001253496A1 (en) * 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
WO2003106692A2 (en) * 2002-06-13 2003-12-24 Merck Patent Gmbh Methods for the identification of all-antigens and their use for cancer therapy and transplantation

Also Published As

Publication number Publication date
JP2010252806A (ja) 2010-11-11
US20050244421A1 (en) 2005-11-03
ES2329461T3 (es) 2009-11-26
AU2003245942A1 (en) 2003-12-31
EP1512014A2 (en) 2005-03-09
EP2110669B1 (en) 2011-08-03
DK1512014T3 (da) 2009-10-05
ATE438857T1 (de) 2009-08-15
WO2003106692A3 (en) 2004-12-23
ATE519115T1 (de) 2011-08-15
EP1512014B1 (en) 2009-08-05
ES2370688T3 (es) 2011-12-21
WO2003106692A2 (en) 2003-12-24
AU2003245942B2 (en) 2008-07-24
EP2110669A1 (en) 2009-10-21
DE60328685D1 (de) 2009-09-17
JP2005529187A (ja) 2005-09-29
CA2489296A1 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
DK1512014T3 (da) Fremgangsmåder til identifikation af alloantigener samt anvendelse deraf til cancerbehandling og transplantation
PT1587532E (pt) Péptidos derivados de survivina e a sua utilização
CY1123535T1 (el) Υποκαταστατο θεραπευτικο τελικο σημειο για βασιζομενη σε anti-ctla-4 ανοσοθεραπεια ασθενειας
WO2003104399A3 (en) CANCER-RELATED GENE AS A TARGET IN CHEMOTHERAPY
AR026946A1 (es) Osteoprotegerina/receptores de factores de necrosis de tumores
MX2021010531A (es) Proteina de fusion bifuncional y uso farmaceutico de la misma.
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
EP1405862A3 (en) Method for the identification of antigenic peptides
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
EA200600344A1 (ru) Антитела против vegf
DK1887014T3 (da) Humane Toll-homologer
PH12021550470A1 (en) Improved anti-flt3 antigen binding proteins
EA201591219A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
DE60114018D1 (de) Von zellen präsentierte peptide
MX2025006010A (es) Anticuerpos psma y usos de los mismos
US9720000B2 (en) Targeted identification of immunogenic peptides
EA202091713A1 (ru) Биологический синтез аминокислотных цепей для получения пептидов и белков
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
ATE496129T1 (de) Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
BR0311720A (pt) Método para mapear e eliminar epitopos de células t
EP3195877A1 (en) Targeted identification of immunogenic peptides
SG11201901435UA (en) Monoclonal antibody against melk and utilization thereof
ATE466588T1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
Bhardwaj et al. 820 Machine learning significantly improves neoantigen-HLA predictions utilizing> 26,000 data points from the PACTImmuneTM Database
WO2020099674A3 (en) Novel c-met and tmx2 antibodies